Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. (United States) has no DMF, CEP or site registration linked in our records. 2 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Orexigen Therapeutics, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/orexigen-therapeutics-inc
Overview
Orexigen Therapeutics, Inc. was a biopharmaceutical company focused on developing pharmaceutical products for the treatment of obesity. The company's main product was Contrave, a combination drug that was intended to help patients with weight management. Orexigen faced financial challenges and eventually entered bankruptcy proceedings.
Therapeutic areas
FDA compliance signals
2 FDA enforcement records linked to this company.
- recall — Class III2018-11-14
Container packaging defect.
- recall — Class III2018-08-22
Defective Container: Customer complaints of punctures in the bottle.
Is this Orexigen Therapeutics, Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.